Omeros (LTS:0KBU) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0KBU Omeros Corp LTS:0KBU
34 GF Score
Price $19.12
! 6 Warning Signs
View Full Analysis

What is Omeros Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.


LTS:0KBU vs STTK, BBOT, XOMA: Short Interest Comparison

For the Biotechnology subindustry, Omeros's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omeros Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's Short Interest distribution charts can be found below:

* The bar in red indicates where Omeros's Short Interest falls into.


LTS:0KBU
34GF Score
Omeros Corp LTS:0KBU
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Omeros Business Description

Other Exchanges OMER:USA3O8:Germany
Address 201 Elliott Avenue West, Seattle, WA, USA, 98119
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
34GF Score

Get the complete analysis for LTS:0KBU

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.12
Price